trending Market Intelligence /marketintelligence/en/news-insights/trending/4VlyuT2usViqGbcMqYC__g2 content esgSubNav
In This List

Hutchison China MediTech seeks regulatory approval for cancer drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Hutchison China MediTech seeks regulatory approval for cancer drug

Hutchison China MediTech Ltd. filed an application with the China Food and Drug Administration, seeking approval for fruquintinib in patients with advanced colorectal cancer.

The application is supported by data from a successful phase 3 trial.

The submission also triggers a $4.5 million milestone payment from Eli Lilly & Co., which is co-developing the drug in China.